Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO5126766
Avutometinib (RO5126766) · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5126766 | DRUG | Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2). |
Inclusion Criteria: * adult patients, \>=18 years of age; * advanced and/or metastatic cancer not amenable to standard therapy; * any solid tumor type (Part 1); malignant melanoma, pancreatic cancer or non-small cell lung cancer (Part 2); * measurable and/or evaluable disease (Part 1), \>=1 measura...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 9 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCB000928 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | Momelotinib |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
Avutometinib, also known as RO5126766, is an investigational small molecule developed by Roche Holding AG (ticker RHHBY) for the treatment of neoplasms, or advanced solid tumors. It is being studied in oncology and has completed a Phase 1 dose-escalation trial. It is not yet approved for any indication.
Avutometinib targets MAP2K1 and MAP2K2, also known as MEK1 and MEK2. It is a small molecule inhibitor of these kinases, which are components of the MAP kinase signaling pathway that is frequently dysregulated in cancer. By inhibiting MAP2K1 and MAP2K2, the drug aims to block tumor cell proliferation.
Avutometinib is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating the drug in patients with advanced solid tumors.
Avutometinib is in Phase 1 clinical development. It has completed one Phase 1 dose-escalation trial in patients with advanced solid tumors. The drug is investigational and has not been approved by the FDA or any regulatory agency for any indication.
Avutometinib has been studied in the Phase 1 trial NCT00773526, titled A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. This completed trial enrolled 52 patients across France, Spain, and the United Kingdom. It was an uncontrolled, non-double-blind study in adults with neoplasms.
Yes, Avutometinib and RO5126766 refer to the same investigational drug. RO5126766 is an alternative name or code used by the developer, Roche Holding AG. Both names identify the same small molecule inhibitor targeting MAP2K1 and MAP2K2.